Article thumbnail

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

By Amir Sonnenblick, Christine Desmedt, Patrick Neven, Sibylle Loibl, Carsten Denkert, Heikki Joensuu, Sherene Loi, Nicolas Sirtaine, Pirkko-Liisa Kellokumpu-Lehtinen, Martine Piccart-Gebhart, Christos Sotiriou, Sylvain Brohée, Debora Fumagalli, Delphine Vincent, David Venet, Michail Ignatiadis, Roberto Salgado, Gert Van den Eynden and Françoise Rothé

Abstract

Background: The likelihood of recurrence in patients with breast cancer who have HER2-positive tumors is relatively high, although trastuzumab is a remarkably effective drug in this setting. Signal transducer and activator of transcription 3 protein (STAT3), a transcription factor that is persistently tyrosine-705 phosphorylated (pSTAT3) in response to numerous oncogenic signaling pathways, activates downstream proliferative and anti-apoptotic pathways. We hypothesized that pSTAT3 expression in HER2-positive breast cancer will confer trastuzumab resistance. Methods: We integrated reverse phase protein array (RPPA) and gene expression data from patients with HER2-positive breast cancer treated with trastuzumab in the adjuvant setting. Results: We show that a pSTAT3-associated gene signature (pSTAT3-GS) is able to predict pSTAT3 status in an independent dataset (TCGA; AUC = 0.77, P = 0.02). This suggests that STAT3 induces a characteristic set of gene expression changes in HER2-positive cancers. Tumors characterized as high pSTAT3-GS were associated with trastuzumab resistance (log rank P = 0.049). These results were confirmed using data from the prospective, randomized controlled FinHer study, where the effect was especially prominent in HER2-positive estrogen receptor (ER)-negative tumors (interaction test P = 0.02). Of interest, constitutively activated pSTAT3 tumors were associated with loss of PTEN, elevated IL6, and stromal reactivation. Conclusions: This study provides compelling evidence for a link between pSTAT3 and trastuzumab resistance in HER2-positive primary breast cancers. Our results suggest that it may be valuable to add agents targeting the STAT3 pathway to trastuzumab for treatment of HER2-positive breast cancer.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Topics: Sciences bio-médicales et agricoles, Breast cancer, FinHer, HER2, Phosphorylated STAT3, Randomised trial, Trastuzumab resistance
Publisher: 'Springer Science and Business Media LLC'
Year: 2015
DOI identifier: 10.1186/s12916-015-0416-2
OAI identifier: oai:dipot.ulb.ac.be:2013/217653
Provided by: DI-fusion
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/2013/ULB... (external link)
  • https://dipot.ulb.ac.be/dspace... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.